Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

According to the recently published report 'Aryl Hydrocarbon Receptor - Drugs In Development, 2022'; Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 32 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes.

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Aryl hydrocarbon receptor is a protein encoded by the AHR gene. It mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. It involved in cell-cycle regulation. It plays an important role in the development and maturation of many tissues. It regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1.

The report 'Aryl Hydrocarbon Receptor - Drugs In Development, 2022' outlays comprehensive information on the Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 4, 17 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Gastrointestinal, Dermatology, Central Nervous System, Infectious Disease, Metabolic Disorders, Ophthalmology and Respiratory which include indications Coronavirus Disease 2019 (COVID-19), Psoriasis, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Atopic Dermatitis (Atopic Eczema), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Inflammatory Bowel Disease, Multiple Sclerosis, Triple-Negative Breast Cancer (TNBC), Type 1 Diabetes (Juvenile Diabetes), Ulcerative Colitis, Unspecified Cancer, Unspecified Dermatological Disorders, Uveitis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Respiratory Distress Syndrome, Alopecia, Androgen-Sensitive Prostate Cancer, B-Cell Non-Hodgkin Lymphoma, Bladder Cancer, Blepharitis, Burkitt Lymphoma, Celiac Disease, Colitis, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Crohn's Disease (Regional Enteritis), Dengue Fever, Graft Versus Host Disease (GVHD), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Keratoconjunctivitis Sicca (Dry Eye), Lupus Nephritis, Mantle Cell Lymphoma, Melanoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Myasthenia Gravis, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Oral Cancer, Osteoarthritis Pain, Pancreatic Ductal Adenocarcinoma, Pemphigus, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma), T-Cell Lymphomas, Transitional Cell Cancer (Urothelial Cell Cancer), Vitiligo, Wet (Neovascular / Exudative) Macular Degeneration and Zika Virus Infections.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)
  • The report reviews Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) – Overview
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) – Companies Involved in Therapeutics Development
Actavalon Inc
Active Biotech AB
Ampio Pharmaceuticals Inc
AnTolRx Inc
Aqilion AB
Artus Therapeutics Inc
Aslan Pharmaceuticals Ltd
Azora Therapeutics Australia Pty Ltd
Bayer AG
Dermavant Sciences Inc
Hercules Pharmaceuticals BV
Ikena Oncology Inc
JAGUAHR Therapeutics Pte Ltd
Magenta Therapeutics Inc
Nogra Pharma Ltd
Pfizer Inc
Phenex Pharmaceuticals AG
Shenogen Pharma Group Ltd
Sol-Gel Technologies Ltd
Welichem Biotech Inc
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) – Drug Profiles
Ampion – Drug Profile
AQ-312 – Drug Profile
ARTX-28 – Drug Profile
AT-177 – Drug Profile
BAY-218 – Drug Profile
BAY-2416964 – Drug Profile
Celiac Disease – Drug Profile
cinnabarinic acid – Drug Profile
Dermatology – Drug Profile
Drug to Agonize Aryl Hydrocarbon Receptor for Type 1 Diabetes – Drug Profile
Drugs to Antagonize AHR for Oncology – Drug Profile
HP-163 – Drug Profile
IK-175 – Drug Profile
Inflammatory Bowel Disease – Drug Profile
JaguAhR – Drug Profile
laquinimod sodium – Drug Profile
Multiple Sclerosis – Drug Profile
-Myasthenia Gravis – Drug Profile
NPD-0614 – Drug Profile
Psoriasis – Drug Profile
Rheumatoid Arthritis – Drug Profile
Small Molecule to Agonize AhR for Type 1 Diabetes and Graft Versus Host Disease – Drug Profile
Small Molecules to Agonize AHR for Inflammatory Bowel Disease – Drug Profile
Small Molecules to Agonize AHR for Psoriasis and Atopic Dermatitis – Drug Profile
Small Molecules to Antagonize AHR for Coronavirus Disease 2019 (COVID-19) and Solid Tumor – Drug Profile
Small Molecules to Antagonize AHR for Triple Negative Breast Cancer – Drug Profile
Small Molecules to Antagonize Aryl Hydrocarbon Receptor for Oncology – Drug Profile
Small Molecules to Antagonize Aryl Hydrocarbon Receptor for Pancreatic Ductal Adenocarcinoma – Drug Profile
SNG-162 – Drug Profile
spanlecortemlocel – Drug Profile
tapinarof – Drug Profile
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) – Dormant Products
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) – Discontinued Products
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) – Product Development Milestones
Featured News & Press Releases
May 24, 2022: FDA approves Dermavant’s VTAMA (tapinarof) cream, 1% for the treatment of Plaque Psoriasis in Adults: first topical novel chemical entity launched for psoriasis in the U.S. in 25 Years
May 16, 2022: Ampio independent committee to conduct investigation
Apr 28, 2022: Ikena Oncology to present data on IK-175 at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
Apr 26, 2022: Active Biotech strengthens the patent protection for laquinimod in eye disorders
Apr 20, 2022: Ampio provides regulatory update
Mar 25, 2022: Dermavant showcases new long-term durability and tolerability data from phase 3 PSOARING 3 trial of tapinarof cream for adults with plaque psoriasis at the 2022 AAD annual meeting
Mar 11, 2022: Dermavant to present new data from the phase 3 PSOARING 3 long-term extension trial of tapinarof cream for adults with plaque psoriasis at the 2022 American Academy of Dermatology Annual Meeting
Mar 02, 2022: Ampio Pharmaceuticals releases positive phase 3 data analysis for Ampion targeting severe Osteoarthritis of the knee (OAK)
Jan 15, 2022: Dermavant presents new patient satisfaction data from PSOARING 3 long term extension trial of tapinarof in adults with plaque psoriasis at the 2022 Winter Clinical Dermatology Conference
Jan 07, 2022: Dermavant to present new data from phase 3 PSOARING program at the 2022 Winter Clinical Dermatology Conference
Dec 10, 2021: Active Biotech: First subject dosed in phase I clinical study with eye-drop formulation of laquinimod
Dec 09, 2021: Dermavant announces publication of PSOARING 1 & 2 pivotal studies of tapinarof in plaque psoriasis in The New England Journal of Medicine
Nov 12, 2021: Ikena Oncology presents data at SITC 36th Annual Meeting describing the indication selection methodology, translational data, and trial in progress for IK-175
Oct 01, 2021: Ikena Oncology to present a trial-in-progress update, translational data, and indication selection methodology for novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development by Stage of Development, 2022
Table 2: Number of Products under Development by Therapy Areas, 2022
Table 3: Number of Products under Development by Indications, 2022
Table 4: Number of Products under Development by Indications, 2022 (Contd..1)
Table 5: Number of Products under Development by Indications, 2022 (Contd..2)
Table 6: Number of Products under Development by Companies, 2022
Table 7: Products under Development by Companies, 2022
Table 8: Products under Development by Companies, 2022 (Contd..1)
Table 9: Products under Development by Companies, 2022 (Contd..2)
Table 10: Products under Development by Companies, 2022 (Contd..3)
Table 11: Number of Products under Investigation by Universities/Institutes, 2022
Table 12: Products under Investigation by Universities/Institutes, 2022
Table 13: Number of Products by Stage and Mechanism of Actions, 2022
Table 14: Number of Products by Stage and Route of Administration, 2022
Table 15: Number of Products by Stage and Molecule Type, 2022
Table 16: Pipeline by Actavalon Inc, 2022
Table 17: Pipeline by Active Biotech AB, 2022
Table 18: Pipeline by Ampio Pharmaceuticals Inc, 2022
Table 19: Pipeline by AnTolRx Inc, 2022
Table 20: Pipeline by Aqilion AB, 2022
Table 21: Pipeline by Artus Therapeutics Inc, 2022
Table 22: Pipeline by Aslan Pharmaceuticals Ltd, 2022
Table 23: Pipeline by Azora Therapeutics Australia Pty Ltd, 2022
Table 24: Pipeline by Bayer AG, 2022
Table 25: Pipeline by Dermavant Sciences Inc, 2022
Table 26: Pipeline by Hercules Pharmaceuticals BV, 2022
Table 27: Pipeline by Ikena Oncology Inc, 2022
Table 28: Pipeline by JAGUAHR Therapeutics Pte Ltd, 2022
Table 29: Pipeline by Magenta Therapeutics Inc, 2022
Table 30: Pipeline by Nogra Pharma Ltd, 2022
Table 31: Pipeline by Pfizer Inc, 2022
Table 32: Pipeline by Phenex Pharmaceuticals AG, 2022
Table 33: Pipeline by Shenogen Pharma Group Ltd, 2022
Table 34: Pipeline by Sol-Gel Technologies Ltd, 2022
Table 35: Pipeline by Welichem Biotech Inc, 2022
Table 36: Dormant Products, 2022
Table 37: Dormant Products, 2022 (Contd..1)
Table 38: Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development by Stage of Development, 2022
Figure 2: Number of Products under Development by Therapy Areas, 2022
Figure 3: Number of Products under Development by Top 10 Indications, 2022
Figure 4: Number of Products by Mechanism of Actions, 2022
Figure 5: Number of Products by Stage and Mechanism of Actions, 2022
Figure 6: Number of Products by Routes of Administration, 2022
Figure 7: Number of Products by Stage and Routes of Administration, 2022
Figure 8: Number of Products by Molecule Types, 2022
Figure 9: Number of Products by Stage and Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings